von Willebrand factor propeptide in vascular disorders: A tool to distinguish between acute and chronic endothelial cell perturbation

Blood

Volumn 94, Issue 1, 1999, Pages 179-185

  Van Mourik, Jan A ^a   Boertjes, Ria ^b   Huisveld, Inge A ^b   Fijnvandraat, Karin ^b   Pajkrt, Dasja ^b   Van Genderen, Perry J J ^b   Fijnheer, Rob ^b  

^a CENTRAL LABORATORY   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DESMOPRESSIN; ENDOTOXIN; VON WILLEBRAND FACTOR;

ARTICLE; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENDOTHELIUM LESION; HUMAN; HUMAN TISSUE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SECRETION; THROMBOTIC THROMBOCYTOPENIC PURPURA; VASCULAR DISEASE;

EID: 0033168804     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.1.179.413k18_179_185     Document Type: Article

References (28)

1. Wagner DD: Cell biology of von Willebrand factor. Annu Rev Cell Biol 6:217, 1990
2. Rubin DB, Wiener-Kronish JP, Murray JF, Green DR, Turner J, Luce JM, Montgomery AB, Marks JD, Matthay MA: Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome. J Clin Invest 86:474, 1990
3. Thompson SG, Kienast J, Pyke SDM, Haverkate F, Van de Loo JCW: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 332:635, 1995
4. Zeigler ZR, Rosenfeld CS, Andrews III DF, Nemunaitis J, Raymond JM, Shaduk RK, Kramer RE, Gryn JF, Rintels PB, Besa EC, George JN: Plasma von Willebrand factor antigen (vWF:AG) and thrombomodulin (TM) levels in adult thrombotic thrombocytopenic purpura/hemolytic syndromes (TTP/HUS) and bone marrow transplant-associated thrombotic microangiopathy (BMT-TM). Am J Hematol 53:213, 1996
5. Blann AD, Davis A, Miller JP, McCollum CN: Von Willebrand factor and soluble E-Selectin in hyperlipidaemia: Relationship to lipids and vascular disease. Am J Hematol 55:15, 1997
6. Lip GYP, Blann A: Von Willebrand factor: A marker of endothelial dysfunction in vascular disorders? Cardiol Res 34:255, 1997
7. Fay PJ, Kawai Y, Wagner DD, Ginsburg D, Bonthron D, Ohlsson-Wilhelm BM, Chavin SI, Abraham GN, Handin RI, Orkin SH, Montgomery RR, Marder VJ: Propolypeptide of von Willebrand factor circulates in blood and is identical to von Willebrand antigen II. Science 232:995, 1986
8. Wagner DD, Fay PJ, Sporn LA, Sinha S, Lawrence SO, Marder VJ: Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells. Proc Natl Acad Sci USA 84:1955, 1987
9. Borchiellini A, Fijnvandraat K, ten Cate JW, Pajkrt D, van Deventer SJH, Pasterkamp G, Meijer-Huizinga F, Zwart-Huinink L, Voorberg J, van Mourik JA: Quantitative analysis of von Willebrand factor propeptide release in vivo: Effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood 88:2951, 1996
10. Vischer UM, Ingerslev J, Wollheim CB, Mestries JC, Tsakiris DA, Haefeli WE, Kruithof EKO: Acute von Willebrand factor secretion from the endothelium in vivo: Assessment through plasma propeptide (vWF:AgII) levels. Thromb Haemost 77:387, 1997
11. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fain AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The AACP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644, 1992
12. Van Genderen PJJ, Prins FJ, Lucas IS, Van Moesdijk D, Van Vliet HHDM, van Strik, R, Michiels JJ: Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythemia: Normalization after cytoreduction of the increased platelet count. Br J Haematol 99,832, 1997
13. Van den Burg PJM, Hospers JEH, van Vliet M, Mosterd WL, Bouma BN, Huisveld IA: Changes in haemostatic factors and activation products after exercise in healthy subjects with different ages. Thromb Haemost 74:1457, 1995
14. Fay PJ: Factor VIII structure and function. Thromb Haemost 70:63, 1993
15. Jilma B, Eichler, HG, Vondrovec B, Breiteneder H, Kyrle PA, Kitzweger E, Kapiotis S, Speiser W: Effects of desmopressin on circulating P-selectin. Br J Haematol 93:432, 1996
16. Fijnheer R, Frijns CJM, Korteweg J, Rommes H, Peters JH, Sixma JJ, Nieuwenhuis HK: The origin of P-selectin as a circulating plasma protein. Thromb Haemost 77:1081, 1997
17. Blann A, Lip GYH, Gareth Beevers D, McCollum CN: Soluble P-selectin in atherosclerosis: A comparison with endothelial cell and platelet markers. Thromb Haemost 77:1077, 1997
18. Suffredini AF, Harpel PC, Parrillo JE: Promotion and subsequent inhibition of plasminogen activator after administration of intravenous endotoxin to normal subjects. N Engl J Med 320:1165, 1989
19. Van Deventer SJH, Büller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A: Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 76:2520, 1990
20. Moake JL: Thrombotic thrombocytopenic purpura. Thromb Haemost 74:240, 1995
21. Van Deventer SJH, Büller HR, ten Cate JW, Sturk A, Pauw W: Endotoxaemia: An early predictor of septicaemia in febrile patients. Lancet 1:605, 1988
22. Vischer UM, Emeis JJ, Bilo HJ, Stehouwer CDA, Thomsen C, Rasmussen O, Hermansen K, Wollheim CB, Ingerslev J: Von Willebrand factor (vWF) as a plasma marker of endothelial activation in diabetes: Improved reliability with parallel determination of the vWF propeptide (vWF:AgII). Thromb Haemost 80:1002, 1998
23. Scott JP, Montgomery RR: Platelet von Willebrand's antigen II: Active release by aggregating agents and a marker of platelet release reaction in vivo. Blood 58:1075, 1981
24. De Romeuf C, Mazurier C: Comparison between von Willebrand factor (VWF) and VWF antigen II in normal individuals and patients with von Willebrand disease. Thromb Haemost 80: 37, 1998
25. Reinders JH, de Groot PhG, Gonsalves MD, Zandbergen J, Loesberg C, van Mourik JA: Isolation of a storage and secretory organelle containing von Willebrand protein from cultured human endothelial cells. Biochim Biophys Acta 804:361, 1984
26. Sporn LA, Marder VJ, Wagner DD: Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell 46:185, 1986
27. Jahroudi N, Lynch DC: Endothelial-cell-specific regulation of von Willebrand factor gene expression. Mol Cell Biol 14:999, 1994
28. Jahroudi N, Ardekani AM, Greenberger JS: Ionizing irradiation increases transcription of the von Willebrand factor gene in endothelial cells. Blood 88:3801, 1996